Recently, the authoritative academic journal Hematology in the field of international hematology published the research papers of Chinese scholars in the form of cover pages. The study found for the first time that atorvastatin can increase the number and function of damaged endothelial progenitor cells in patients with hormonal null immune thrombocytopenia, thereby repairing megakaryocyte function impairment, increasing the number of platelets, and reducing bleeding in patients. This brings good news for patients with hormone-negative thrombocytopenia.
Thrombocytopenia is usually considered as an autoimmune disease that can occur in children and adult common bleeding disorders. Clinical manifestations often include skin ecchymosis, gums, and gastrointestinal bleeding. The author of the paper and the professor of Department of Hematology of People's Hospital of Peking University Professor Huang Xiaojun pointed out that glucocorticoids are the first-line treatment commonly used in patients with immune thrombocytopenia, but there are still 15% to 50% of patients with hormone therapy or hormone dependence, collectively referred to as hormone ineffective Type of immune thrombocytopenia. The pathogenesis of steroid-poor immune thrombocytopenia is not yet clear, and lack of effective clinical intervention strategies is an important clinical scientific problem that needs urgent solution.
Huang Xiaojun's group used a prospective paired clinical cohort study, combined with primary bone marrow vascular endothelial progenitor cells and megakaryocyte in vitro research platforms and prospective small sample clinical studies to demonstrate for the first time that the number and function of bone marrow vascular endothelial progenitor cells were involved in hormone-invalid immunity. The incidence of thrombocytopenia; atorvastatin can be through the number and function of damaged endothelial progenitor cells in patients with such diseases, partial repair of megakaryocyte function damage; and the safety and efficacy of oral atorvastatin treatment. This study reveals for the first time the new pathogenesis of hormone-negative immune thrombocytopenia and clinical intervention strategies from the perspective of bone marrow vascular endothelial progenitor cells. It will lay a theoretical foundation for the establishment of a novel prevention and control system and is expected to improve clinical prognosis.
According to the review of Blood magazine, Huang Xiaojun's work suggested that "immune thrombocytopenia is not only a disease but also a heterogeneous disease with multiple pathogenesis. This work not only initiates immune thrombocytopenia. New research fields and potential new therapeutic strategies for the clinical intervention of immune thrombocytopenia have laid a foundation for the development of prospective randomized controlled clinical trials."
Cosmetics are compound mixtures made from various raw materials after reasonable blending and processing. There are many types of cosmetics raw materials with different properties. According to the raw material properties and uses of cosmetics, it can be roughly divided into two categories: base raw materials and auxiliary raw materials. The former is a main raw material of cosmetics, which occupies a large proportion in cosmetic formulations, and is the main functional substance in cosmetics. The latter is responsible for shaping, stabilizing or imparting color, fragrance and other characteristics to cosmetics. These substances are not used in large amounts in cosmetic formulations, but are extremely important. Cosmetics are chemical mixtures made of natural, synthetic or extracted substances with different functions as raw materials and processed through production processes such as heating, stirring and emulsification.
Collagen peptide, Arbutin, Coenzyme Q10, GSH, Cosmetic Raw Materials, lipoic acid
Xi'an Gawen Biotechnology Co., Ltd , https://www.ahualynbio.com